Dyslipidémie
.webp/jcr:content/Cardio2_cover%20(2).webp)
Articles
2024 ESC Guidelines for the management of chronic coronary syndromes
Felicita Andreotti, Italy; Christiaan J M Vrints, Belgium
What is PRALUENT®?
PRALUENT®: a powerful PCSK9i that ticks all the boxes1–4
PRALUENT is a PCSK9i that reduces the levels of LDL-C in the blood.2 It is a fully human IgG1 monoclonal antibody that works by inhibiting the binding of PCSK9 to LDL- receptors. As a result, PRALUENT increases the number of LDL-receptors available to clear LDL, thereby lowering LDL-C levels.2 Elevated LDL-C levels have been significantly associated with cardiovascular disease such as heart attacks and strokes.1
Acute LDL-C reduction post ACS: Strike early and strike strong: From evidence to clinical practice
A clinical consensus statement of Association for acute cardiovascular care (ACVC), in collaboration with European association of preventive cardiology (EAPC) and the European Society of Cardiology working group on cardiovascular Pharmacotherapy Krychtiuk KA, et al. Eur Heart J Acute Cardiovasc Care. 2022;11(12):939–949.
%20(1).png)
.jpg/jcr:content/image%20(24).jpg)
.jpg/jcr:content/image%20(81).jpg)
.svg)
.svg)
